Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.35 USD | -0.68% | -12.60% | -25.46% |
Apr. 18 | Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing | MT |
Apr. 16 | Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.46% | 1.74B | |
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B |
- Stock Market
- Equities
- RXRX Stock
- News Recursion Pharmaceuticals, Inc.
- Goldman Sachs Adjusts Recursion Pharmaceuticals' Price Target to $10 from $32, Keeps Neutral Rating